Suzhou Brainlight Biomedical Technology Co., Ltd (abbreviated as “BLT medicine”) was officially established on April 30, 2025, dedicated to the research and development of innovative drugs in the field of major brain diseases. We focus on central nervous system (CNS) diseases such as Parkinson's disease, depression, epilepsy, migraine, stroke, and amyotrophic lateral sclerosis, as well as their complex comorbidities. We aim to provide safe, effective and accessible treatment solutions for patients worldwide.
Since our inception, we have assembled a team of experts with extensive experience in drug development in the field of CNS diseases, and have built a AI-powered all-round and complete innovative drug research and development platform. Based on this concept “anchoring the key target, acting in concert through multiple pharmacological mechanism”, we are dedicated to the development of new drugs for CNS disorders, to overcome the limited clinical efficacy of drugs targeting a single target or with a single mechanism. Relying on the independently research and development platform, we have built a rich pipeline of ongoing research projects, mainly focusing on innovative drug research for major brain diseases such as Parkinson's disease, depression, epilepsy, migraine, and glioma.
Since our inception, we have assembled a team of experts with extensive experience in drug development in the field of CNS diseases, and have built a AI-powered all-round and complete innovative drug research and development platform. Based on this concept “anchoring the key target, acting in concert through multiple pharmacological mechanism”, we are dedicated to the development of new drugs for CNS disorders, to overcome the limited clinical efficacy of drugs targeting a single target or with a single mechanism. Relying on the independently research and development platform, we have built a rich pipeline of ongoing research projects, mainly focusing on innovative drug research for major brain diseases such as Parkinson's disease, depression, epilepsy, migraine, and glioma.
